C-Rad AB (publ) (LON:0R44)

Market Cap	91.00M +9.9%
Revenue (ttm)	34.04M -8.9%
Net Income	2.37M -7.7%
EPS	0.07 -7.9%
Shares Out	n/a
PE Ratio	38.43
Forward PE	n/a
Dividend	0.01 (0.02%)
Ex-Dividend Date	May 8, 2026

Volume	7
Open	33.95
Previous Close	n/a
Day's Range	33.95 - 33.95
52-Week Range	25.70 - 35.40
Beta	0.73
Analysts	n/a
Price Target	n/a
Earnings Date	May 6, 2026

About C-Rad AB

C-Rad AB (publ) develops, manufactures, and sells products and systems with applications in radiotherapy for the treatment of cancer in Europe, the Middle East, Africa, the Americas, and the Asia Pacific. The company offers Catalyst+ HD, a patient positioning, intra-fraction motion management, and respiratory gating solution for conventional and stereotactic treatment delivery; Catalyst+, a solution for patient set up and intra-fraction breath hold reproducibility; Catalyst+ PT, a surface image guided radiation therapy solution that supports pr...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2004
• Employees: 110
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0R44

Financial Performance

In 2025, C-Rad AB's revenue was 441.90 million, a decrease of -5.78% compared to the previous year's 469.00 million. Earnings were 10.46 million, a decrease of -81.47%.

Financial numbers in SEK